Przejdź do zawartości
Merck
Wszystkie zdjęcia(1)

Kluczowe dokumenty

539136

Millipore

Protease Inhibitor Cocktail IV

liquid, for the inhibition of serine proteases, cysteine proteases, aspartic proteases and metalloproteases. This small molecule/inhibitor is primarily used for Protease Inhibitors applications.

Synonim(y):

Protease inhibitor cocktail

Zaloguj sięWyświetlanie cen organizacyjnych i kontraktowych


About This Item

Kod UNSPSC:
12352200
NACRES:
NA.54

Nazwa produktu

Protease Inhibitor Cocktail Set IV, The Protease Inhibitor Cocktail Set IV controls the activity of Protease. This small molecule/inhibitor is primarily used for Protease Inhibitors applications.

Formularz

liquid

producent / nazwa handlowa

Calbiochem®

warunki przechowywania

OK to freeze

rozpuszczalność

water: soluble

Warunki transportu

wet ice

temp. przechowywania

−20°C

Opis ogólny

A cocktail of four protease inhibitors with broad specificity for the inhibition of aspartic-, cysteine-, metallo-, and serine-proteases. Recommended for fungal and yeast cell extracts. Each vial contains 100 mM AEBSF, HCl (Cat. No. 101500), 1.5 mM E-64 (Cat. No. 324890), 2 mM Pepstatin A (Cat. No. 516481), and 500 mM 1,10-Phenanthroline (Cat. No. 516705). Supplied with a data sheet. Note: 1 set = 5 x 1 ml.
The Protease Inhibitor Cocktail Set IV controls the activity of Protease. This small molecule/inhibitor is primarily used for Protease Inhibitors applications.

Specyficzność

Inhibits a broad spectrum of serine proteases, cysteine proteases, aspartic proteases, and metalloproteases.

Zastosowanie

Protease Inhibitor Cocktail Set IV, is a cocktail of four protease inhibitors with broad specificity for the aspartic, cysteine, metallo & serine-proteases. Recommended for fungal & yeast cells.

Działania biochem./fizjol.

Primary Target
aspartic-, cysteine-, metallo-, and serine-proteases
Product does not compete with ATP.

Ostrzeżenie

Toxicity: Toxic (F)

Postać fizyczna

In 1 ml DMSO.

Rekonstytucja

Protease Inhibitor Cocktail Set IV can be used at a 1:100-1:1000 dilution for most applications.

Inne uwagi

Due to the nature of the Hazardous Materials in this shipment, additional shipping charges may be applied to your order. Certain sizes may be exempt from the additional hazardous materials shipping charges. Please contact your local sales office for more information regarding these charges.

Informacje prawne

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Ta strona może zawierać tekst przetłumaczony maszynowo.

Piktogramy

Exclamation markEnvironment

Hasło ostrzegawcze

Warning

Zwroty wskazujące rodzaj zagrożenia

Klasyfikacja zagrożeń

Acute Tox. 4 Oral - Aquatic Acute 1 - Aquatic Chronic 1 - Eye Irrit. 2 - Skin Irrit. 2

Kod klasy składowania

10 - Combustible liquids

Klasa zagrożenia wodnego (WGK)

WGK 3

Temperatura zapłonu (°F)

188.6 °F - Information refers to the main ingredient.

Temperatura zapłonu (°C)

87 °C - Information refers to the main ingredient.


Certyfikaty analizy (CoA)

Poszukaj Certyfikaty analizy (CoA), wpisując numer partii/serii produktów. Numery serii i partii można znaleźć na etykiecie produktu po słowach „seria” lub „partia”.

Masz już ten produkt?

Dokumenty związane z niedawno zakupionymi produktami zostały zamieszczone w Bibliotece dokumentów.

Odwiedź Bibliotekę dokumentów

Joseph V Geisberg et al.
Current protocols in molecular biology, 128(1), e101-e101 (2019-09-11)
Here we describe CLIP-READS, a technique that combines elements of crosslinking and immunoprecipitation (CLIP) and 3' region extraction and deep sequencing (READS), to provide a genome-wide map of mRNA 3' isoform binding by a given messenger ribonucleoprotein (mRNP). In CLIP-READS
Chao Luo et al.
Oncology letters, 21(2), 161-161 (2021-02-09)
The effects of microRNAs (miRNAs/miRs) on glioblastoma have attracted the attention of researchers in the last 7 years. However, the role of miR-640 and its targeted gene, Slit guidance ligand 1 (SLIT1), in the development of glioblastoma are not yet
Matthew M Seavey et al.
Current protocols in pharmacology, Chapter 5, Unit 5-Unit 5 (2011-09-22)
Systemic Lupus Erythematosus (SLE) is a debilitating and often fatal autoimmune disease that involves multiple organ systems. It can develop for years before being diagnosed. Current treatments for SLE usually involve the use of cytotoxic or immunosuppressive agents that can

Nasz zespół naukowców ma doświadczenie we wszystkich obszarach badań, w tym w naukach przyrodniczych, materiałoznawstwie, syntezie chemicznej, chromatografii, analityce i wielu innych dziedzinach.

Skontaktuj się z zespołem ds. pomocy technicznej